Rituxan for ALL

Last Modified: September 23, 2007


Dear OncoLink "Ask The Experts,"

My oncologist has started a treatment regimen of Rituxan for Acute Lymphocytic Leukemia, Ph+. I cannot find any research that indicates that Rituxan is used for treatment of this disease. I have only found where it is used for the treatment of lymphomas and to get patients ready for transplants. Can you clarify this?


Selina M. Luger, MD, Director of the Leukemia Program and Assistant Professor of Medicine at the University of Pennsylvania, responds:

Rituxan is a monoclonal antibody drug that is often used to treat lymphoid malignancies. The term "lymphoid" refers to anything involving lymphatic tissue, i.e. lymph nodes.

Acute Lymphocytic Leukemia , also known as ALL, is a type of lymphoid malignancy that travels through the blood. There have been reports of patients treated with Rituxan in combination with other therapeutic agents for ALL, both Ph-negative and Ph-positive types (Ph=Philadelphia chromosome). I am not aware of treatment with Rituxan as a single agent (given alone) for ALL. Treatment for Ph-positive disease should include one of the tyrosine kinase inhibitors (such as Gleevec/Imatinib or dasatinib).


Breaking news: Supreme Court votes to uphold Affordable Care Act Subsidies
by Christina Bach, MSW, LCSW, OSW-C
June 26, 2015

Related News

Exposure tied to B-cell acute lymphoid leukemia but not acute myeloid leukemia or T-cell ALL

Oct 8, 2010

Exposure tied to B-cell acute lymphoid leukemia but not acute myeloid leukemia or T-cell ALL

Pediatric High-Risk Leukemia Survival Has Improved Over Time

Jul 25, 2011

Improved AML/ALL outcomes following allogeneic, non-allogeneic hematopoietic cell transplantation

Heterogeneity Characterizes Induction Failure in Child ALL

Apr 12, 2012

Pediatric patients with induction failure often present with high-risk features